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Abstract 
 This method developed in the toxicology department at the Cuyahoga County Medical 
Examiner’s Office (CCMEO) detects 40 benzodiazepines and metabolites along with several z-
drugs in blood and urine by liquid chromatography tandem mass spectrometry. A sample amount 
of 0.5 mL was used to detect analytes in postmortem drug facilitated sexual assault and impaired 
driving cases. Twenty-nine analytes met criteria for quantification while the remaining 14 were 
used as qualitative indicators. Bias and precision results for quality controls met criteria, staying 
within ±15% except for clonazolam and etizolam which were within ±20%. Quantitative reporting 
criteria which included dilution integrity was met for 25 analytes. Isomeric pairs, meclonazepam 
and methylclonazepam along with -hydroxyalprazolam and 4-hydroxyalprazolam, were 
separated and showed sufficient recovery. Urine and blood samples were analyzed together with 
matrix effects >25% and no effect on validation data. The method has been in use at CCMEO for 
several months and has be utilized in over 200 samples. In the future, more analytes may be added 
and reference materials for qualitative analytes will be obtained to enable quantification. 
 
  
  
2 
Introduction 
  In 2016, drug overdose deaths totaled at 63,632, with nearly 40,000 deaths involving an 
opioid. Overdose deaths climbed to over 70,000 in 2017 with upwards of 50,000 involving an 
opioid.1 The increase in overdose deaths can be attributed to easily accessible opioid analogs, 
sometimes deemed designer drugs, purchased through the internet.  Most are synthesized in illicit 
labs overseas and are marketed as ‘research chemicals’ due to their unpredictability. Some effects 
are nearly identical to the parent drug while others display a higher potency with a possibility of 
deadly effects. Until recently, there was a lack of analytical techniques for these novel compounds 
and general drug screens could not determine toxicity of these compounds.2 The dramatic increase 
in synthetic opioids has driven development of new methods to extract and quantify these drugs in 
postmortem samples. Gas-chromatography mass spectrometry methods are currently in use but are 
starting to be replaced with more sensitive instrumentation such as liquid chromatography tandem 
mass spectrometry (LC-MS/MS).3 
 LC-MS/MS is becoming the future of forensic toxicology. Liquid chromatography enables 
the separation of molecules through the use of a column and two separate phases. A moving mobile 
phase is used to carry samples through the instrument while the stationary phase actually separates 
the analytes. A sample is injected onto the column along with solvent, each compound interacts 
differently with the stationary phase based on its properties. Analytes that interact more strongly 
with the stationary phase elute at a slower retention time while less interaction causes the 
compounds to elute quicker. Once through the column, analytes are carried to the mass 
spectrometer where each molecule is ionized. Mass analyzers then separate the analytes and their 
mass to charge ratio (m/z) is detected. The analytes undergo a second transformation which 
fragments the parent into product ions that are quantified after mass analysis. The detection of 
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specific parent and product ions are used to uniquely identify analytes making it an excellent 
technique for proteins, polymers and pharmaceuticals.4 
 Designer fentanyl analogs have received much attention in recent years. Fentanyl-related 
overdoses soared from 2013 to 2018, resulting in the discovery of over 15 fentanyl analogs.5 
Groups such as the Toxicology Department at the Cuyahoga County Medical Examiner’s Office 
began developing methods to keep up with the number of cases they were seeing. On the forefront 
of this research, a method to quantify fentanyl, carfentanil, norfentanyl and three other prominent 
analogs using UHPLC-MS/MS was developed.6 Methods are now being expanded to identify 
unique isomers and isobars as well as more analogs.7,8 While advances have been made to analyze 
designer fentanyl analogs, other classes of drugs still pose a threat and require more research.  
 Benzodiazepines and z-drugs are among the most prescribed medications for mental 
disorders such as insomnia, anxiety and epilepsy. These drugs exhibit anxiolytic, hypnotic and 
muscle-relaxant effects due to their ability to depress the central nervous system. Their calming 
effects have influenced the production of designer analogs and the creation of black markets which 
allows users to obtain the drugs without a prescription. Misuse of these drugs can lead to impaired 
neuropsychological function and abuse with other opioids increases the risk of overdose 
deaths.9,10,11 With the emergence of studies on the dangers of benzodiazepine abuse, a method to 
analyze the occurrence of these drugs which can result in fatalities is imperative.  
 Current methods only detected a handful on analytes in either urine or blood.12,13 A new 
comprehensive method that encompasses not only prescription medicines but also designer drugs 
and metabolites will increase the effectiveness. Methods thus far have required separate batches 
for different matrices and creation of a single procedure for both matrices will increase result 
acquisition in less time. Public health professionals and law enforcement agencies can use this 
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information to monitor fluctuations in usage. In turn, professional can alter the availability and 
diminish further abuse of these drugs. 
 
Methods 
Chemicals and Prepared Reagents 
 Acetonitrile (ACN), hexane, formic acid (98+%), ammonium hydroxide (28-30%), sodium 
phosphate monobasic monohydrate (NaH2PO4•H2O) and sodium phosphate dibasic anhydrous 
(Na2HPO4) were purchased from Fisher Scientific (Fair Lawn, NJ, United States). Methanol, water 
and ethyl acetate were also purchased from Fisher Scientific and were HPLC grade. Rapid 
Hydrolysis (HYD) Buffer (20 mL) was purchased from Integrated Micro-Chromatography 
Systems (Columbia, SC, United States) along with -glucuronidase enzyme (IMCSzyme®, 10 
mL, >50,000 Fishman units/mL).  Reference sheep blood containing anticoagulant 
ethylenediaminetetraacetic acid (EDTA) was purchased from HEMOSTAT Laboratories (Dixon, 
CA, United States).  Blank urine was obtained in house from staff members without daily 
medications to ensure it could be used as a clean reference matrix. 
 Several reagents in the procedure are prepared fresh in lab as needed. Sodium phosphate 
buffer at pH 6 was prepared by dissolving 1.7 g of Na2HPO4 and 12.1 g NaH2PO4•H2O in deionized  
water to reach a 0.1 M concentration in a 1-L flask. A 10:90 methanol:ACN solution was also 
prepared fresh for protein precipitation by adding ice-cold ACN to 10 mL of methanol in a 100-
mL volumetric flask. Solid-phase extraction (SPE) elution solvent was also prepared fresh by 
adding 2 mL ammonium hydroxide to 98 mL ethyl acetate to obtain a 2% solution.  
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Analytes and Standards 
 The analytes consisted of (±)-zopiclone, 2-hydroxyethylflurazepam, 3-
hydroxyflunitrazepam, 4-hydroxyalprazolam, 7-aminoclonazepam, 7-aminoflunitrazepam, 
alprazolam, bromazolam, clobazam, clonazepam, clonazolam, delorazepam, deschloroetizolam, 
diazepam, diclazepam, estazolam, etizolam, flualprazolam, flubromazepam, flubromazolam, 
flunitrazepam, flunitrazolam, flurazepam, lorazepam, lormetazepam, meclonazepam, 
methylclonazepam, midazolam, N-desalkylflurazepam, N-desmethylclobazam, N-
desmethylflunitrazepam, nitrazepam, nitrazolam, nordiazepam, oxazepam, oxazepam 
glucuronide, phenazepam, temazepam, triazolam, zaleplon, zolpidem, α-hydroxyalprazolam, α-
hydroxymidazolam and α-hydroxytriazolam. Deuterated internal standards (ISTDs) were obtained 
for twenty-two analytes and consisted of 7-aminoclonazepam-D4, 7-aminoflunitrazepam-D7, 
alprazolam-D5, clonazepam-D4, delorazepam-D4 , diazepam-D5, estazolam-D5, etizolam-D3, 
flunitrazepam-D7, flurazepam-D10, lorazepam-D4, midazolam-D4, N-desalkylflurazepam-D4, 
nordiazepam-D5, oxazepam-D5, phenazepam-D4, temazepam-D5, zaleplon-D4, zolpidem-D7, 
zopiclone-D4, α-hydroxyalprazolam-D5 and α-hydroxymidazolam-D4. 
 The analytes and ISTDs were purchased from Cayman Chemical (Ann Arbor, MI), 
Cerilliant Corporation (Round Rock, TX), and Lipomed Inc, (Cambridge, MA). The compounds 
were obtained in solid (1 mg) or liquid (1 or 0.1 mg/mL) form and were diluted to 10,000 or 
100,000 g/L in ACN to prepare stock solutions at different target concentrations. A working 
calibrator solution was prepared by adding stock solution to ACN to obtain the desired working 
concentration: nordiazepam, diazepam, flubromazepam and nitrazepam were prepared at 1,000 
g/L; zaleplon, -hydroxymidazolam, temazepam, clobazam, N-desalkylflurazepam, -
hydroxytriazolam, phenazepam, bromazolam, 2-hydroxyehtylfurazepam, lormetazepam, 3-
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hydroxyflunitrazepam, N-desmethylflunitrazepam, N-desmethylclobazam at 500 g/L; 7-
aminoclonazepam, midazolam, -hydroxyalprazolam, clonazolam, alprazolam, lorazepam, 
oxazepam, estazolam, meclonazepam, diclazepam, delorazepam, flualprazolam, nitrazolam, 
flunitrazolam, methylclonazepam, 4-hydroxyalprazolam at 250 g/L; and the remaining ten 
analytes were prepared at 100 g/L, zolpidem, (±)-zopiclone, clonazepam, deschloroetizolam, 
etizolam, flubromazolam, flunitrazepam, 7-aminoflunitrazepam, flurazepam and triazolam.  
 One calibrator solution was prepared containing each analyte proportional to their 
individual working concentrations. A pipette was used to transfer 0.50, 0.25 or 2.5, 0.125 and 
0.050 mL for analytes at 1,000 g/L, 500 g/L, 250 g/L and 100 g/L working concentrations 
respectively into a 50-mL flask. Acetonitrile was added to reach the full 50-mL. Seven test tubes 
were filled with 0.5 mL blank sheep blood and calibrator solution was added in increments of 10, 
20, 50, 100, 200, 300 and 400 L to reach the target analytes (Table 1). A quality control (QC) 
solution was prepared to obtain the same concentration as the calibrator solution. Three test tubes 
containing 0.5 mL blank sheep blood were prepared as QC’s at a low, medium and high level using 
30, 180 and 350 L of QC solution. The urine matrix required a positive hydrolysis QC which was 
represented by adding 56.5 L of 2,500 g/L oxazepam glucuronide to 0.5 mL blank urine. An 
ISTD solution was prepared by adding 0.10 or 1.0 mL of 100,000 or 10,000 g/L stock solutions 
into a flask and ACN was added to reach 50 mL.  
 
Table 1: Calibrator levels according to analyte LOD 
 
Column1 Column2 Column3 Column4 Column5 Column6 Column7 Column8
LOD L1 L2 L3 L4 L5 L6 L7
LLOQ ULOQ
(µg/L)
1.0 2 4 10 20 40 60 80
2.5 5 10 25 50 100 150 200
5.0 10 20 50 100 200 300 400
10.0 20 40 100 200 400 600 800
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Instrumentation 
All instrumentation was provided by CCMEO. A Thermo Scientific™ Vanquish™ Flex 
LC System connected to a TSQ Quantis™ MSMS was used for analyte separation and 
identification. The LC contained an Accucore™ Phenyl-Hexyl (Ph-6) column with a Guard 
cartridge, courtesy of Thermo Scientific™. Phenyl-Hexyl columns allow for selectivity of both 
phenyl and alkyl phases. They are suited for polar, aromatic compounds such as the analytes 
detected in this method. A guard cartridge protects the column by filtering impurities out of the 
sample. Two different mobile phases: A and B were used. Mobile Phase A was prepared using 1 
mL formic acid in a 1 L flask of LC-MS grade water to obtain a 0.1% formic acid concentration. 
Mobile phase B contained 0.1% formic acid as well but in ACN. Stocks of each mobile phase were 
prepared and changed as needed. In order to change the mobile phase, flow was halted and the 
new mobile phase added, the lines were then purged to remove any air bubbles. A flow gradient 
was used with a flow rate of 0.5 mL and initial conditions of 20% mobile phase B and 80% mobile 
phase A. Twenty percent mobile phase B lasted for 0.1 min and increased non-linearly to 50% 
over 17 minutes, it then increased linearly to 60% over 2.5 minutes and ramped linearly again to 
95% over 0.5 minutes. Mobile phase B was maintained at 95% for 1.5 minutes at which it was 
returned to initial conditions over 0.5 minutes and then re-equilibrated for 2 minutes (Figure 1). 
The non-linear gradient equation was published by Sofalvi et al. The column oven was kept at 
40C while the autosampler was kept at 5C. The injection volume was 10 L and was controlled 
by the Thermo Scientific™ Chromeleon™ 7.2 SR4 and Xcalibur™ 4.1 software. 
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Figure 1: Flow gradient using MPB and MPA over 24-minute run time 
 
 A heated electrospray ionization source (H-ESI) with a spray voltage of 3.5 kV was used 
to create ions for introduction into the MS. The temperatures of the source and ion transfer tube 
were 350 and 250C respectively. The instrument was used in positive ionization mode to form 
protonated analytes. Multiple reaction monitoring with a cycle time of 0.6 seconds allowed 
entrance into the collision cell for only pre-selected ions. The peak width to cycle time ratio was 
used to estimate the number of data points obtained across a peak. Each analyte and ISTD was 
directly infused to obtain the precursor, quantifier and qualifier ions, collision energies (CE) and 
radio frequency (RF) lens voltages (Table 2). The retention time for each analyte was used for 
identification along with two transitions and the ratio of qualifier to quantifier ions. The Thermo 
TSQ Quantis™ 3.0 SP1 and TraceFinder™ 4.1 SP3 were used to obtain and process the data from 
the mass spectrometer. 
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Table 2: Analyte identifiers obtained through direct infusion 
 
Analyte Precursor	(m/z) QUANT	(m/z) QUAL	(m/z) CE	Quant/Qual	(V) RF	Lens	(V)
(±)-Zopiclone-D4 393 217 33 105
(±)-Zopiclone 389 245 217 33/17 104
7-Aminoclonazepam-D4 290 226 25 180
7-Aminoclonazepam 286 222 250 25/20 180
7-Aminoflunitrazepam-D7 291 138 29 185
 7-Aminoflunitrazepam 284 135 227 27/25 180
Zolpidem-D7 315 242 36 198
Zolpidem 308 235 263 35/26 201
a -Hydroxymidazolam-D4 346 328 21 182
a -Hydroxymidazolam 342 324 203 21/26 182
Midazolam-D4 330 295 27 213
Midazolam 326 291 223 27/38 207
Flurazepam-D10 398 315 23 174
Flurazepam 388 315 288 22/24 156
Deschloroetizolam 309 255 280 24/24 177
Nitrazepam 282 236 207 24/34 157
Nordiazepam-D5 276 213 28 171
Nordiazepam 271 208 165 27/28 171
Flunitrazolam 338 292 264 27/36 202
Nitrazolam 321 274 246 26/36 189
Zaleplon-D4 310 240 28 134
Zaleplon 306 236 264 27/20 177
4-Hydroxyalprazolam 325 307 280 18/20 145
a -Hydroxyalprazolam-D5 330 302 26 202
a -Hydroxyalprazolam 325 297 216 25/39 198
N-Desmethylflunitrazepam 300 254 198 25/38 162
Oxazepam-D5 292 246 23 142
Oxazepam 287 241 269 22/14 137
a -Hydroxytriazolam 359 331 277 27/35 213
Estazolam-D5 300 272 25 181
Estazolam 295 267 205 24/40 179
Clonazolam 354 308 280 27/36 214
N-Desmethylclobazam 287 245 210 19/32 133
2-Hydroxyethylflurazepam 333 211 305 36/20 177
Lorazepam-D4 325 233 31 150
Lorazepam 321 303 229 14/31 153
Clonazepam-D4 320 274 26 183
Clonazepam 16 214 241 37/36 174
Flualprazolam 327 292 223 26/42 215
N-Desalkylflurazepam-D4 293 230 29 153
N-Desalkylflurazepam 289 140 226 29/28 175
Alprazolam-D5 314 286 27 209
Alprazolam 309 281 205 26/41 207
Flubromazolam 371 292 223 27/44 236
Flunitrazepam-D7 321 275 27 179
Flunitrazepam 314 268 239 25/34 175
Temazepam-D5 306 260 22 137
Temazepam 301 255 177 22/39 137
Flubromazepam 333 226 184 29/31 187
Bromazolam 353 325 205 28/43 215
Triazolam 343 308 239 26/42 213
Diazepam-D5 290 262 22 176
Diazepam 285 257 228 22/24 176
Delorazepam-D4 309 210 35 184
Delorazepam 305 140 206 30/35 184
Meclonazepam 330 284 238 26/43 176
Clobazam 301 259 224 20/33 136
Lormetazepam 335 317 177 13/41 142
Etizolam-D3 346 310 22 213
Etizolam 343 314 310 25/22 213
Phenazepam-D4 353 210 35 199
Phenazepam 349 206 184 36/31 201
3-Hydroxyflunitrazepam 330 284 238 26/43 138
Methylclonazepam 330 284 255 32/35 171
Diclazepam 319 227 154 31/29 181
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Method Validation 
 Method validation followed SWGTOX Guidelines which outlines sample preparation and 
data acquisition/processing parameters. Each step should include reference materials for the 
analytes of interest to ensure accuracy and optimization. Five different toxicologists participated 
in the validation on five separate days. Seven different concentrations were used to establish linear 
calibration curves. Each concentration required five replicates through each of five separate runs, 
allowing the values to be compared to prove accurate quantification. Analytes that used analog 
ISTDs were required to meet a 0.99 value for the coefficient of determination (R2) while ISTD 
using homolog ISTD had to only meet an R2 value of 0.98. The target LOD was tested to half the 
lower limit of quantification (LLOQ). The linear calibration curves were then used to calculate an 
estimated LOD for each analyte. The standard deviation of the y-intercept divided by the average 
slope was multiplied by 3.3 to obtain the estimated LOD.  
Each QC level was tested in triplicate along with the LLOQ using blank blood. This was 
done for each batch across five days with the low QC being three times the LLOQ. These values 
were used to determine the bias and precision of the method across each run. At each concentration, 
the maximum bias was ±20% while the precision was not allowed to exceed 20%. Dilution 
integrity was also tested in triplicate over five days using blank blood at the same concentration as 
the QC solution along with 1/2, 1/5 and 1/10 dilutions.  Dilutions allow samples to be re-analyzed 
quantitatively in case they are above the ULOQ. The discrepancy between dilutions must be within 
±20% as to not negatively affect the method’s bias and precision. Precision within and between 
days was calculated using a one-way analysis of variance (ANOVA). Ten times the upper limit of 
quantification (ULOQ) was used to determine the presence of carryover between runs in a batch. 
Any concentration below the LOD was considered to have no carryover. Oxazepam glucuronide 
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was used as the positive QC to test hydrolysis performance with an acceptance of ±20% of the 
target concentration. The low and high QCs were used to evaluate any ion suppression or 
enhancement which also had an acceptance criterion of ±20%. When the threshold is exceeded, 
there may be impacts on the LOD, LLOQ, bias and precision which needs to be evaluated. Previous 
casework with blood and urine samples that had previously tested negative for analytes by 
screening with enzyme-linked immunosorbent assay (ELISA), enzyme multiplied immunoassay 
technique (EMIT) and LC-MS/MS were used to evaluate interference.  
  
Sample Preparation 
 Test tubes were obtained and labeled for all urine standards and cases. Each tube was filled 
with 0.5 mL of blank urine or case sample. All samples received 50 L ISTD solution and 200 L 
Rapid HYD Buffer then were vortexed for 7 seconds. Caps were loosely placed on each tube and 
placed into a water bath for incubation at 55C for 30 minutes. During this time, tubes were labeled 
according to the blood standards and cases. Blank and sample blood (0.5 mL) were added to their 
respective labeled tubes and ISTD (50L) was added. After hydrolysis, the urine samples were 
returned to the batch to undergo extraction with the blood samples. All cells were lysed by addition 
of 0.5 mL DI water to each tube. The tubes were vortexed and allowed to rest for 10 minutes at 
room temperature. While vortexing, 1.5 mL of freshly prepared ice-cold 10:90 methanol:ACN was 
added slowly to the center of the tube until a visual separation was seen. The samples were placed 
in the freezer to rest for 10 minutes at 20 ± 5C. Samples were centrifuged at 3,500 rpm (2,800 x 
g) for 10 minutes resulting in a supernatant that was poured into a new glass culture tube. Three 
milliliters of 0.1 M sodium phosphate buffer (pH 6) was added and then vortexed for 7 minutes. 
A positive pressure manifold from United Chemical Technologies, Inc. (UCT) (Bristol, PA, United 
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States) fitted with mixed-mode, strong cation exchange and hydrophobic, extraction cartridge from 
Phenomenex Inc (Torrance, CA, United States) was used to conduct SPE. The columns were pre-
conditioned with 3 mL methanol, 3 mL DI water and 3 mL 0.1 M sodium phosphate buffer (pH 
6). Each solution was eluted under 5 psi positive pressure without over drying the columns. 
Samples were then poured into the columns and eluted under 2 psi positive pressure. The columns 
were then washed with a series of 3 mL DI water and 3 mL 5% (v/v) ACN in 0.1 M phosphate 
buffer (pH 6) with each step being followed by an elution at 5 psi positive pressure. The columns 
were dried fully for 10 minutes using full positive pressure and then checked for full dryness with 
a bulb. Two milliliters of hexane was added to each column and eluted at 5 psi positive pressure 
then followed by 1 minute of full pressure. Analyte elution was conducted using 3 mL of the 
freshly prepared elution solvent followed by full pressure for 30 seconds and repeating. The 
conical tubes containing the analytes were evaporated to dryness using a Biotage Turbo-Vap 
maintained at 40C. The precipitate was reconstituted using 100 L 20% MPB/80% MPA and 
then vortexed for 7 seconds. Tubes were then centrifuged at 3,500 rpm for 5 minutes and the 
supernatants were transferred to conical inserts and placed in LC-MS/MS vials.  
 
Results and Discussion 
 The method started with infusion of 52 analytes to obtain identifiers such as QUAL and 
QUANT ions, CE and RF lens voltage. Once a CAL was prepared, the analytes were extracted 
using the osmotic lysing, SPE and reconstitution steps detailed in the method to test the R2 criteria 
(Figure 2). The phenyl hexyl column was able to well separate the analytes due to their aromatic 
rings. ISTDs were used as reference materials, and paired up to analytes with similar fragmentation 
patterns. Eight of the original 52 analytes were removed from the method as they failed to meet R2 
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criteria with any ISTD. Those removed included zolpidem phenyl-4-COOH, pyrazolam, 
loprazolam, ketazolam, tetrazepam, prazepam, cloniprazepam and flutoprazepam. The remaining 
43 analytes met the criteria (Figure 3). 
 
 
 
 
 
 
Figure 2: Chromatograms at blood CAL L1 (top) and CAL L7 (bottom) 
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Figure 3: Linear calibration curves of common benzodiazepines 
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Another flualprazolam metabolite, -hydroxyflualprazolam, was added to the method due 
to the frequency of cases that contain the parent drug. Lorazepam, more commonly known as 
Ativan, experienced an out of range ion ratio in the L1 calibrator. The calibration curve cannot be 
accepted if any of the seven levels are out of range for a number of reasons. In this case, the original 
infusion report for lorazepam was re-evaluated for other viable quant ions. The new ion, 302.9 
m/z, put the ion ratio within range and enabled a common sedative to be properly identified.  
 A previous method for fentanyl analogs by Sofalvi et al. provided starting ground for the 
procedure. In this method, a casework batch consists of a blank, unextracted test mix, blood matrix 
blank, negative blood, blood calibrators L1-7, three positive blood QC levels, negative urine, three 
positive urine QC levels and the chosen cases. A 0.5 mL sample amount was used as well as 50 
L ISTD in all tubes with the exception of the blanks. Urine samples were originally hydrolyzed 
for upwards of 2 hours but through multiple trials, it was determined that 30 minutes was sufficient 
using a genetically modified -glucuronidase. After samples underwent osmotic lysing, proteins 
were precipitated out using cold methanol:acetonitrile which has been shown to result in a cleaner 
sample preparation. The separated samples were rested in the freezer and the supernatant was hand 
poured into a new tube. There was no need to transfer the supernatant with a pipette due to a clean 
separation and frozen precipitate.  
 The choice of extraction column was made after much deliberation between Phenomenex® 
and UCT Inc. Both cartridges were tested for extraction of all analytes, recovery and price. 
Multiple extractions used both cartridges in the same batch. The UCT cartridges were more 
consistent across each extraction, meeting calibration curve criteria for most analytes. 
Phenomenex® cartridges were priced slightly higher than UCT but obtained higher area counts.  
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Bias and Precision 
 Bias and precision were obtained from five trials across five days. Data was entered into 
an Excel file to calculate and store statistical values for bias and precision, matrix effects, dilution 
integrity and carryover. Twenty-nine analytes met quantitation criteria with the availability of a 
QC while the remaining 14 were used for qualitative reporting only. Bias and imprecision were 
tested between and within-day for each analyte and all quantitative analytes at the LLOQ were 
<20% for both bias and imprecision with the exception of flunitrazepam between-day at 23.9% 
and diclazepam within-day at 42.7% (Table 3). The remaining analytes QCs were not purchased 
in order to save cost, and so they were only analyzed qualitatively. All analytes met identification 
criteria at the specified LOD. Clonazolam and etizolam were the only two analytes who did not 
meet ±15% QC criteria for bias, inter-day and intra-day results. Clonazolam bias was 18.8% and 
17.8% for the medium and high QCs respectively. Etizolam exceed criteria for inter-day high QC 
precision with 16.50%. These two exceptions were still within ±20%. All other quantitative 
analytes met ±15% criteria (Table 4). 
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Table 3: Estimated LOD, mean, bias and precision in blood at the LLOQ 
 
LOD Target Mean Bias RSD (%)
Analyte (µg/L) (µg/L) (µg/L) (%) Intra- Inter-
(±)-Zopiclone 0.5 2 1.9 -2.7 7.62 8.30
7-Aminoclonazepam 2.0 5 4.6 -8.3 11.10 14.02
7-Aminoflunitrazepam 0.4 2 1.9 -4.3 11.69 13.97
Zolpidem 0.4 2 2.1 2.7 10.37 9.26
a -Hydroxymidazolam 3.2 10 9.0 -10.1 10.63 11.05
Midazolam 1.6 5 4.8 4.3 9.14 9.90
Flurazepam 0.4 2 2.1 4 6.45 6.63
Deschloroetizolam 0.7 2 1.8 -8 11.14 12.27
Nitrazepam 8.6 20 18.7 -6.5 8.79 12.04 QUAL
Nordiazepam 6.4 20 19.9 -0.3 9.00 10.65
Flunitrazolam 2.1 5 4.0 -20.8 10.73 13.31 QUAL
Nitrazolam 1.7 5 4.2 -15.3 9.21 9.22 QUAL
Zaleplon 2.3 10 10.8 7.9 7.73 7.41
4-Hydroxyalprazolam 2.5 5 4.6 -8.9 18.82 24.30
a -Hydroxyalprazolam 1.5 5 5.3 6.4 7.64 9.85
N -Desmethylflunitrazepam 4.9 10 7.1 -28.6 15.17 24.55
Oxazepam 1.2 5 5.2 4.7 7.03 7.69
a -Hydroxytriazolam 5.8 10 7.7 -22.7 8.23 22.61 QUAL
Estazolam 1.6 5 5.1 2.5 6.98 9.38
Clonazolam 2.6 5 5.1 2.9 9.17 13.22
N-Desmethylclobazam 2.4 10 10.3 3.5 5.77 6.88
2-Hydroxyethylflurazepam 3.1 10 8.5 -15.1 12.79 15.45
Lorazepam 1.3 5 5.3 5.1 8.17 8.64
Clonazepam 0.4 2 2.1 4.3 6.66 5.85
Flualprazolam 3.0 5 4.9 -2.3 8.47 12.83
N -Desalkylflurazepam 2.8 10 10.2 2.5 8.08 8.80
Alprazolam 1.4 5 5.5 9.5 8.07 9.64
Flubromazolam 1.2 2 2.2 9.3 7.56 13.48
Flunitrazepam 2.2 2 2.0 -0.3 8.88 23.91
Temazepam 2.1 10 10.6 5.8 7.67 6.98
Flubromazepam 9.8 20 18.6 -6.8 8.84 12.31
Bromazolam 4.6 10 9.0 -9.7 9.49 26.71 QUAL
Triazolam 1.1 2 2.2 8.3 9.83 17.28
Diazepam 18.5 20 18.6 -7.1 9.62 13.28
Delorazepam 1.2 5 5.2 4.3 6.79 7.96
Meclonazepam 2.4 5 5.3 6.1 8.69 15.12 QUAL
Clobazam 4.6 10 9.0 -10.2 27.43 37.57 QUAL
Lormetazepam 6.6 10 11.9 19.3 10.01 18.66 QUAL
Etizolam 0.5 2 2.0 -1 10.27 11.49
Phenazepam 4.4 10 10.2 1.8 8.58 15.86
3-Hydroxyflunitrazepam 7.4 10 8.6 -14.3 16.93 26.41 QUAL
Methylclonazepam 5.0 5 4.8 -4 15.25 28.02 QUAL
Diclazepam 6.3 5 4.3 -14.3 23.21 42.73
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Table 4: Mean, bias and precision data for 29 analytes in blood at the QCs
 
 
 
Matrix Effect 
 This method combined batches of blood and urine samples, a necessary advancement for 
drug analysis methods. Matrices were tested together to ensure no interference between the two 
and then both sample types were run in the same batch during validation. Matrix effects were 
<25% with the exception of -hydroxyalprazolam, flualprazolam, alprazolam, flubromazolam and 
triazolam at both the low and high QCs while phenazepam and diclazepam at the high QC only 
Target Mean Bias Target Mean Bias Target Mean Bias
Analyte (%) Intra- Inter- (%) Intra- Inter- (%) Intra- Inter-
(±)-Zopiclone 6 6.0 0.1 2.58 3.19 36 35.8 -0.4 1.72 4.18 70 69.0 -1.5 2.59 5.84
7-Aminoclonazepam 15 15.5 3.1 4.04 7.43 90 93.7 4.1 3.19 5.40 175 178.5 2.0 3.39 5.71
Bromazepam 60 56.1 -6.5 2.81 17.76 360 337.3 -6.3 3.77 5.98 700 673.5 -3.8 2.51 5.16
7-Aminoflunitrazepam 6 5.9 -1.6 1.45 3.77 36 36.0 -0.1 1.43 4.29 70 67.6 -3.4 2.98 4.93
Zolpidem 6 6.1 1.1 1.86 3.77 36 36.5 1.3 2.34 3.52 70 70.5 0.7 2.41 3.84
a -hydroxymidazolam 30 31.5 4.9 1.56 3.47 180 189.6 5.4 2.03 4.07 350 345.3 -1.4 2.32 3.08
Midazolam 15 14.9 -0.9 3.47 3.47 90 92.5 2.8 2.01 4.55 175 175.4 0.2 2.75 3.64
Flurazepam 6 6.2 3.2 5.69 7.13 36 38.9 8.2 5.43 4.81 70 73.9 5.5 3.63 6.02
Deschloroetizolam 6 6.2 3.2 3.18 2.77 36 40.2 11.7 2.69 5.78 70 76.5 9.3 2.94 3.94
Nordiazepam 60 62.5 4.1 2.55 4.10 360 378.0 5.0 2.47 3.63 700 731.4 4.5 2.73 3.62
Zaleplon 30 29.9 -0.5 1.34 3.73 180 179.4 -0.3 2.18 3.89 350 353.3 0.9 2.57 4.05
a -hydroxyalprazolam 15 16.0 6.6 1.92 6.89 90 93.5 3.9 3.88 5.68 175 181.7 3.8 2.64 6.13
Oxazepam 15 15.7 5.0 1.62 3.53 90 96.7 7.5 1.42 3.61 175 189.6 8.4 3.20 4.12
Estazolam 15 15.2 1.1 1.62 3.79 90 91.5 1.6 1.9 3.96 175 176.2 0.7 3.05 3.93
Clonazolam 15 17.7 18.3 4.94 5.21 90 106.9 18.8 2.33 4.74 175 206.1 17.8 3.32 4.33
Lorazepam 15 14.8 -1.4 2.01 4.93 90 86.5 -3.9 2.47 3.88 175 167.2 -4.5 2.22 4.65
Clonazepam 6 5.7 -5.8 2.96 4.57 36 33.7 -6.3 2.28 3.88 70 66.3 -5.3 2.75 4.12
Flualprazolam 15 13.7 -8.4 5.15 6.45 90 83.1 -7.7 3.74 8.58 175 160.0 -8.6 2.32 4.63
N -Desalkylflurazepam 30 31.0 3.4 2.18 4.39 180 186.3 3.5 1.69 4.07 350 362.6 3.6 2.62 3.97
Alprazolam 15 14.9 -0.8 1.66 5.22 90 88.7 -1.4 1.47 3.55 175 175.2 0.1 1.97 4.32
Flubromazolam 6 5.5 -8.7 4.19 7.85 36 31.6 -12.2 3.91 10.00 70 64.1 -8.4 2.73 6.49
Flunitrazepam 6 6.4 6.3 6.26 13.70 36 38.2 6.0 6.26 13.70 70 70.8 1.2 3.52 6.41
Temazepam 30 29.3 -2.2 1.66 4.57 180 181.1 0.6 2.07 3.57 350 364.1 4.0 2.78 3.73
Flubromazepam 60 60.6 1.1 2.74 5.45 360 361.3 0.4 3.22 4.40 700 690.1 -1.4 3.22 4.94
Triazolam 6 6.1 1.8 8.25 8.27 36 36.0 -0.1 6.98 11.82 70 72.6 3.8 4.15 7.62
Diazepam 60 67.1 11.8 5.34 11.31 360 376.3 4.5 9.83 8.9 700 719.3 2.8 6.00 8.83
Delorazepam 15 14.8 -1.6 2.63 3.55 90 89.1 -1.0 2.46 3.74 175 172.4 -1.5 3.71 4.12
Etizolam 6 6.4 6.9 3.20 3.16 36 40.4 12.1 1.32 3.56 70 77.9 11.3 2.81 16.50
Phenazepam 30 31.6 5.3 2.14 6.42 180 181.7 0.9 3.59 4.78 350 347.4 -0.7 3.27 5.25
Diclazepam 15 15.8 5.0 4.30 8.48 90 85.3 -5.2 4.32 5.56 175 162.2 -7.3 5.65 9.26
(ng/mL) (ng/mL) (ng/mL)
RSD (%) RSD (%) RSD	(%)
Low QC Medium QC High QC
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(Table 5). These percentages had no effect on validation parameters, LOD, LLOQ, R2 and QCs, 
as the ISTDs were altered proportionally to the analytes. The urine matrix was validated against 
the blood calibration curve and will be used as a qualitative indicator. 
 
Table 5: Matrix effect data for 29 quantitative analytes in blood at low and high QC 
 
 
 
Analyte
ME RSD ME RSD ME RSD ME RSD
(±)-Zopiclone -5.35 17 -3.64 18 -8.83 6 -7.74 4
7-Aminoclonazepam -3.10 12 2.64 11 -9.13 3 -10.40 6
7-Aminoflunitrazepam 1.50 5 3.12 6 -3.96 5 -6.53 6
Zolpidem 8.08 5 4.18 5 -9.42 6 -13.77 4
a -hydroxymidazolam 0.08 20 -1.20 22 -13.25 35 -16.66 35
Midazolam 7.72 13 9.43 12 0.68 12 -3.94 10
Flurazepam 6.36 16 -3.46 17 -12.96 19 -21.84 19
Deschloroetizolam 5.09 5 3.18 6 -3.28 6 -10.38 6
Nordiazepam -6.51 5 -8.42 4 -14.45 7 -20.74 7
Zaleplon -6.43 12 -8.30 17 -18.82 25 -22.58 24
a -hydroxyalprazolam 117.00 23 134.72 25 105.00 35 112.85 34
Oxazepam 5.15 4 3.28 2 -5.79 4 -10.83 4
Estazolam 17.89 3 16.92 4 6.11 3 2.43 3
Clonazolam -4.26 13 8.54 18 -15.41 26 -10.29 30
Lorazepam -0.79 5 1.93 4 -10.57 5 -12.25 5
Clonazepam 2.07 6 5.33 3 -6.87 4 -8.20 3
Flualprazolam 42.16 5 137.93 10 27.19 5 112.50 9
N-Desalkylflurazepam -8.74 21 -10.94 24 -22.13 38 -26.24 37
Alprazolam 137.95 11 137.93 10 -112.33 10 112.50 9
Flubromazolam 38.62 9 137.93 10 24.65 6 112.50 9
Flunitrazepam -6.75 17 -6.49 23 -18.20 30 -22.89 33
Temazepam -9.98 19 -9.98 23 -21.26 36 -24.65 35
Flubromazepam -1.89 6 -8.42 4 -10.29 8 -20.74 7
Triazolam -10.01 14 116.60 23 -21.52 33 83.07 36
Diazepam -5.82 6 -8.42 4 -14.66 8 -20.74 7
Delorazepam -9.15 6 -8.63 5 -17.94 9 -21.57 9
Etizolam -5.42 17 -1.40 23 -21.27 36 -22.90 35
Phenazepam -23.56 24 -20.10 26 -35.81 42 -35.72 40
Diclazepam -11.22 7 -7.47 8 -23.16 11 -68.23 8
Low QC
Analyte (%) ISTD (%)
High QC
Analyte (%) ISTD (%)
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Stability 
Extracted samples were stored at 5C and reinjected at 24, 48 and 96 hours to evaluate the 
stability of the sample. Nearly all analytes were stable showing <20% degradation through the 
time frame. Only one analyte, 4-hydroxyalprazolam, showed ≥20% degradation after the first 24-
hour period.  
 
Dilution Integrity 
  Some analytes, (±)-zopiclone, flualprazolam, flubromazolam and diclazepam experienced 
>20% bias in dilution integrity at 1/2, 1/5 and 1/10 dilution factors (Table 6). This indicates 
dilutions for these analytes do not meet criteria for quantitative reporting. During analysis, if these 
analytes land beyond the range of the calibration curve, the samples will not be re-analyzed using 
a dilution but instead will be indicated with >ULOQ. The quantitative analytes met reporting 
criteria within the range of the calibration curves while the remaining 14 analytes met qualitative 
reporting criteria. Twenty-five quantitative analytes met reporting criteria for dilution integrity as 
well.  
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Table 6: Dilution Integrity data for 29 analytes in blood at various dilution factors 
 
 
 
 
 
 
 
Bias (%) Bias (%) Bias (%)
Intra- Inter- Intra- Inter- Intra- Inter-
(±)-Zopiclone -26.8 2.4 10.2 -29.6 7.7 12.3 -31.5 6.9 14.2
7-Aminoclonazepam -6.3 3.6 4.3 -11.6 9.2 9.2 -16.5 6.7 9.3
7-Aminoflunitrazepam -8.9 3.8 4.6 -10.7 9 8.5 -17.1 6.6 8
Zolpidem -0.8 2.7 3.9 -2.1 8.5 7.9 -6.2 7 7.6
a -hydroxymidazolam 3 3 3.6 6 8.3 8.1 1.8 6.7 8.2
Midazolam -8.3 3.5 3.9 -8.8 8.9 8.5 -12.9 6.7 8.3
Flurazepam -1 7.5 9.1 -5.1 8.7 9.7 -11.1 6.6 10
Deschloroetizolam 7.3 3.5 6.3 13.1 8.9 8.8 6.6 7.1 8.4
Nordiazepam 2.2 2.9 3.7 2.2 8.9 8.1 -1.8 6.5 0.4
Zaleplon -2.9 2.8 5 -5.2 8.5 7.9 -9.7 7 7.5
a -hydroxyalprazolam 0.5 2.3 6.1 -1 9.4 9.4 -2.7 7.8 8.7
Oxazepam -0.4 2.5 0.4 -2 9.3 8.6 -7.8 6.4 7.5
Estazolam -6.8 2.5 4.2 -6.5 8.5 8 -10.9 7 7.4
Clonazolam 0.1 4.5 4.8 4.5 8 8.2 -1.7 5.9 8.8
Lorazepam -12.1 2.8 4.1 -12.7 9.4 8.8 -15.9 7.3 7.6
Clonazepam -9.8 2.3 4 -12 9.8 8.6 -16.7 7.4 7.8
Flualprazolam -20.2 5.3 8.3 -26.6 9.6 9.2 -29.7 7.2 9.1
N-Desalkylflurazepam 1.4 2.4 3.3 1.3 8.6 8 -4.2 6 7.8
Alprazolam -11.2 2.6 5.4 -12.3 8.7 8.4 -16.8 7.2 7.8
Flubromazolam -18.3 7.8 10 -24.9 9.3 9.6 -27.7 7.1 9.2
Flunitrazepam -13.4 12.9 15 -2.2 10.6 11.4 -0.4 7.8 9.9
Temazepam -2.8 2.6 4.8 7 8.8 8.3 -12.2 6.1 7.2
Flubromazepam 1.2 4.7 5.8 1.6 8.5 8.3 -2 6.9 8.3
Triazolam -11 11.5 11.2 -14.3 9.2 9.1 -18.2 7.3 8.4
Diazepam 2.5 9.4 9.9 10.4 8.9 8.6 11.6 7.4 9.4
Delorazepam -2.3 3.1 4.4 -1.6 8.2 7.9 -5.1 6.9 8.8
Etizolam -4.8 3.9 5.6 -4.3 8.6 8 -10.9 6.1 7.4
Phenazepam -1.6 3.5 4.4 0.8 9.4 8.8 -0.9 7.6 7
Diclazepam -21.7 4 9.7 -21.6 9.6 13.1 -24.2 8.6 16.5
Dilution Factor
Analytes
RSD (%) RSD (%)RSD (%)
1/2 1/5 1/10
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Carryover and Selectivity 
 At 10 times the ULOQ no carryover was observed. There are eight isobaric pairs within 
this method: N-desmethylflunitrazepam (300.07 m/z) with estazolam-D5 (300.10 m/z),  alprazolam 
(309.08 m/z) with delorazepam-D4 (309.04 m/z), zaleplon-D4 (310.15 m/z) with the carbon-13 
isotope of deschloroetizolam (310.11 m/z), flunitrazepam (314.08 m/z) with alprazolam-D5 
(314.11 m/z), lorazepam (321.01 m/z) with flunitrazepam-D7 (321.13 m/z), -hydroxyalprazolam 
(325.08 m/z) with lorazepam-D4 (325.04 m/z), midazolam-D4 (330.1033 m/z) with -
hydroxymalprazolam-D5 (330.1091 m/z) and finally triazolam (343.04 m/z) with etizolam (343.07 
m/z). Baseline resolution of these pairs allows for quantification.  
 Two pairs of structural isomers were separated without the use of a chiral column. 
Meclonazepam (330 m/z) and methylclonazepam (330 m/z) (Figure 2) share common transitions 
such as the QUANT ion (284 m/z) and QUAL ions (238 m/z and 255 m/z). The other pair of 
isomers are hydroxylated metabolites of alprazolam, -hydroxyalprazolam (325 m/z) and 4-
hydroxyalprazolam (325 m/z) (Figure 3). Methylclonazepam (330.05 m/z) and 3-
hydroxyflunitrazpam (330.08 m/z) also have identical retention times at 17.03 minutes and the 
appearance of interference limits reporting of these analytes quantitatively. If only one of these 
two analytes is present in a sample, qualitative identification is an option due to their distinct ion 
ratios. 
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Figure 4: Structures (MolView) and LLOQ extraction of meclonazepam and methylclonazepam 
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Figure 5: Structures (MolView) and LLOQ extraction of 4-hydroxyalprazolam and -
hydroxyalprazolam  
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Conclusion 
 This method has the largest capacity for benzodiazepine and z-drug analysis to date. A 
small sample volume of only 0.5 mL enabled the quantitation of 29 out of 43 analytes. Both urine 
and blood matrices are able to be analyzed in a single batch without interference. Two unique pairs 
of structural isomers with the same QUAL and QUANT ions were separated without the need for 
a chiral column.  
 This is the start of a multi-generational method. It is currently limited by its inability to 
quantify 3-hydroxyflunitrazepam and methylclonazepam if both are present in a sample due to 
their identical retention times. There were also 4 analytes that did not meet the criteria for dilution 
integrity, resulting in a reporting limitation when a dilution is used. The capacity of the method 
can also be expanded to add in the analytes that were removed as well as validating more analytes 
for quantitative reporting through the acquisition of QCs.  
 There have been impaired driving cases where benzodiazepines were the only substance 
found in the defendant’s sample. Research has been conducted on the psychoactive components 
of these drugs deeming that long-term usage can impair the user. This method can further these 
studies by providing comprehensive data across a variety of analytes.      
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Appendix: Safety considerations 
Personal Protective Equipment (PPE) 
 PPE was required to be worn at all times in the laboratory. This included a lab coat, 
goggles and some type of protective gloves.  In this experiment, latex gloves provided protection 
from chemical reagents and prevented contamination. In the instrument room, PPE guidelines 
were lessened as lab coat, gloves and goggles were required when working with chemicals to 
prepare instrument solvents. Instrument maintenance was completed while wearing gloves and 
goggles to prevent eye injury or chemical spills on the hands. Gloves were worn while working 
on the computers in case of biohazardous contamination. 
 
Sanitation 
 Before entering the instrument room or leaving the lab, hands were washed to remove 
contaminants. An eye wash and safety shower were located within the lab in case of emergency. 
Lab floors and counters were cleaned daily. 
 
Biohazardous material 
 Biological blood and urine samples were used throughout this method. It was essential to 
take precautions when working with these samples especially in open test tubes. Anything that 
came in contact with biological material was disposed of in biohazardous waste containers that 
were emptied at the end of each week. 
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Glass material 
 Glass ware was used for almost every step in this process. Caution was taken when glass 
ware was used to prevent shattering. Any broken glass ware was disposed of in specified sharps 
bins which were also emptied weekly.  
 
Chemicals 
 Chemicals were not used without prior authorization. All chemicals were handled 
carefully and used and stored under the fume hood. Specific waste containers were used to 
dispose of chemical waste. Empty chemical bottles were left under the hood with the cap 
removed for any remnants to evaporate before disposal.  
 
Injury 
 In case of injury, all incidents should be reported to the supervisor. For less serious 
injuries, supervisors should be notified before actions are taken. In case or more serious injuries 
including chemicals in the eyes, the eye wash should be used immediately.  
